Drug Sponsors

Vital announces workforce, cost reductions

Wednesday, September 9, 2015

Vital Therapies, a biotherapeutic company developing ELAD, a cell-based therapy targeting the treatment of liver failure, has announced a workforce reduction of about 30% and plans to institute across the board expense reductions to conserve capital. The company expects to record personnel-related severance charges of $1.2 million, primarily in the quarter ending Sept. 30.

[Read More]

Amneal launches new biosciences unit

Thursday, August 27, 2015

Amneal Pharmaceuticals has launched Amneal Biosciences, a wholly owned subsidiary. Amneal Biosciences will focus exclusively on the commercialization of high-barrier-to-entry generic and specialty pharmaceuticals such as injectables, oncologics and biosimilars to healthcare providers globally.

[Read More]